Quality of Life Kinoko Platinum AHCC 750 Mg 60 Ct by Quality of Life

Product Information

VEGAN WITH NO FILLERS, BINDERS OR ADDITIVES. At Time Health we believe in clean nutrition which is why you won’t find any nasty stuff in our products including any binders, fillers or additives, unlike some of our competitors. JS was a recipient of various unrestricted research grants supporting preclinical studies on AHCC prior to 2014 from Amino Up, Ltd. AminoUp’s leading supplement, AHCC, was launched in 1987, following an evaluation of more than 100 different mushroom species, and systematically tested for optimized manufacturing.

This phase II study confirmed findings from the two previous pilot studies that demonstrated that AHCC supplementation will modulate the host immune system to eliminate persistent high-risk HPV infections ( 14). While it may not help all patients, in the absence of other systemic treatments, clinicians can recommend AHCC, which is a readily available nutritional supplement that offers a good chance of clearance of persistent HPV infections. The original contributions presented in the study are included in the article/supplementary materials. Further inquiries can be directed to the corresponding author. Ethics Statement A) AHCC 3g supplementation (B) AHCC 1g supplementation. IFN-β is a Type-1 IFN often associated with virulence of chronic viral infections. Chronic viral infections are often associated with high levels of IFN-β that leads to suppression of the production of IFN-γ and NK/T-cell cytotoxic cell immunity. It was observed in both pilot studies AHCC supplementation suppression of host IFN-β levels below level of 25 pg/mL that lead to modulation of the cytotoxic cell immunity to a successful, durable clearance of persistent, high risk HR-HPV infections.Conclusion: Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections. In the growth inhibition assays supplementation with AHCC for 72 h did not achieve any cell growth inhibition in any of the four human cervical cancer cell lines tested at clinically relevant concentration of 0.42 mg/mL. However, potential direct cytotoxicity was observed the concentration to achieve 50% growth inhibition (IC 50), for AHCC ranged from 2.3 to 4 mg/mL in the four human cervical cancer cell lines however this is well above clinically achievable systemic concentrations. These results are summarized in Table 1. This study was supported by the NIH-NCI Small Grants Program for Cancer Research (1R03CA212935), which had no involvement in the study design, data collection, data analysis, and interpretation or writing of the manuscript or its publication. Conflict of Interest There are some limitations to data presented. First, in the preclinical setting there is no established HR-HPV animal model which has also been a challenge for in the pre-clinical development of HPV vaccines. As a surrogate a human tumor infected with HR-HPV was employed to determine if the HR-HPV infection could be cleared with AHCC supplementation and was durable response after AHCC supplementation was stopped. In addition, in both the pre-clinical and clinical studies it would be ideal to confirm eradication with quantitative PCR methods as well as evaluate other immune markers such as CD8+ T-cells or natural killer (NK) cells but due to limited funding and being exploratory study, an exhaustive immune panel evaluation could not be completed. However, in the ongoing phase II confirmation study these studies are being evaluated.

The same team undertook a preliminary clinical study of 10 women, persistently infected with high-risk HPV, that was encouraging enough to lead to a larger clinical trial. Smith is now undertaking a NIH-funded, double-blinded, placebo-controlled study of 50 women with persistent high-risk HPV infection with results expected to be published by 2021. FRIENDLY, PULLULAN CAPSULES. Pullulan is the next generation in encapsulation, derived from tapioca and processed with water. AminoUp has worked to improve human immunity for more than 35 years. Its approach is simple: to enhance the natural ability of foods that positively affect human health. This was the first double-blind, placebo-controlled clinical study to demonstrate that the nutritional supplement, AHCC, is effective in eliminating persistent, high-risk HPV infections with durable response in those patients who achieved an IFN-β level below 20 pg/ml. Overall, AHCC was well tolerated and had comparable adverse effects as compared to placebo. Patients must agree to return to clinic for follow-up visits (including repeat HPV testing) and complete medication administration calendar.

Publisher’s Note

After 12 weeks of supplementation, the percentage change in alanine aminotransferase (ALT) levels was significantly different between the placebo and both AHCC groups (1 g of AHCC ® and 3 g of AHCC ®). Serum levels of tumor necrosis (p < 0.05) and interleukin-1β ( p < 0.01) were significantly lower, while those of adiponectin were higher in both AHCC ® groups than in the placebo group (p < 0.01). AHCC ® supplementation for 12 weeks may improve the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with alcohol-induced mildly elevated liver enzyme levels. The liver enzyme levels, lipid profiles, insulin resistance, and scores on fatigue and stress-related questionnaires did not show significant differences between the groups (p < 0.05); however, cytokine levels did show significant differences (TNF-α, IL-1β, and adiponectin, p < 0.05). Comparing the percentage changes at 12 weeks as analyzed by a paired t-test, a decrease in liver enzymes in both AHCC groups and a change in IL-1β and adiponectin in the 1-g AHCC ® group were found to be statistically significant. When analyzed with ANOVA, the percentage changes of serum levels of inflammatory cytokines, such as TNF-α (p < 0.05) and IL-1β (p < 0.01), were lower in the AHCC ® supplementation groups than in the placebo group. Serum levels of adiponectin were higher in both AHCC ® groups than in the placebo group (p < 0.05). Dr Kohei Homma, executive senior director of business development (left) and president and COO, Kentaro Kitadate in front of the AHCC culture tank. He believes AHCC is also worth investigating for its potential to help with some of the world’s other significant health challenges, including the growing problem of antibiotic resistance.

For example, ‘superbugs’, bacteria that are resistant to all available antibiotics, are expected to be responsible for more deaths than cancer by 2050, according to a review commissioned by the UK Government. Homma says that AHCC may help to support the immune system to enable the body to better fight infection, and potentially to reduce the use of strong antibiotics.

Discussion

UK MADE & HIGH QUALITY. This product is manufactured in the UK to GMP standards, ensuring the highest quality. In the absence of an available vaccine against coronavirus, there is broad interest in alternative approaches to immune system maintenance.